Precision Medicine Expertise Aignostics specializes in developing best-in-class insights for precision medicine through AI technologies and access to multimodal clinical datasets, providing unique selling points for pharmaceutical companies looking to enhance drug discovery and clinical trials.

Strategic Location Advantage With operations in both Berlin and New York, Aignostics is strategically positioned to tap into two key innovation hubs, offering a competitive edge in attracting biopharma partners interested in collaborating with a company at the forefront of healthcare tech advancements.

Solid Financial Backing Backed by leading VC investors and with a revenue ranging between $10M - $50M, Aignostics has the financial stability to engage in large-scale projects, making them an attractive partner for companies seeking long-term collaborations with a financially secure entity.

Tech-Forward Approach Utilizing a tech stack that includes GitLab, scikit-learn, and Google among others, Aignostics demonstrates a commitment to cutting-edge technologies, appealing to companies looking to innovate and incorporate the latest tools into their healthcare solutions.

Established Market Presence Being a spin-off from Charité Berlin, one of the world's most esteemed university hospitals, Aignostics benefits from a strong reputation and a legacy of scientific rigor, positioning them as a trusted partner for companies seeking to align with established industry expertise.